Format

Send to

Choose Destination
J Pharmacol Exp Ther. 2018 Jul 9. pii: jpet.118.249409. doi: 10.1124/jpet.118.249409. [Epub ahead of print]

NYX-2925 is a novel NMDA receptor modulator that induces rapid and long-lasting analgesia in rat models of neuropathic pain.

Author information

1
Aptinyx, Inc.; nayerehhaack@aptinyx.com.
2
Aptinyx, Inc.
3
Aptinyx.

Abstract

NYX-2925 is a novel N-methyl-D-aspartate (NMDA) receptor modulator that is currently being investigated in Phase 2 clinical studies for the treatment of painful diabetic peripheral neuropathy and fibromyalgia. Previous studies demonstrated that NYX-2925 is a member of a novel class of NMDA receptor-specific modulators that affect synaptic plasticity processes associated with learning and memory. Studies here examined thermal and mechanical analgesic effects of NYX-2925 administration in rat peripheral chronic constriction nerve injury (CCI) and streptozotocin (STZ)-induced diabetic mechanical hypersensitivity. Additionally, NYX-2925 was examined in formalin-induced persistent pain and the tail flick model of acute nociception. Oral administration of NYX-2925 resulted in rapid and long-lasting analgesia in both of the neuropathic pain models and formalin-induced persistent pain, but was ineffective in the tail flick model. The analgesic effects of NYX-2925 were blocked by the systemic administration of NMDA receptor antagonist 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid (CPP). Microinjection of NYX-2925 into the medial prefrontal cortex (mPFC) of CCI rats resulted in analgesic effects similar to those observed following systemic administration, whereas intrathecal administration of NYX-2925 was ineffective. In CCI animals, NYX-2925 administration reversed deficits seen in a rat model of rough-and-tumble play. Thus, it appears that NYX-2925 may have therapeutic potential for the treatment of neuropathic pain, and the data presented here supports the idea that NYX-2925 may be acting centrally to ameliorate pain and modulate negative affective states associated with chronic neuropathic pain.

KEYWORDS:

CNS pharmacokinetics; N-methyl-D-aspartate (NMDA); analgesics; behavior; cognition; hypersensitivity; ligand gated ion channels; neuropathic pain; pain; synaptic plasticity

PMID:
29986951
DOI:
10.1124/jpet.118.249409
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center